@megtirrell Is that not just talking then through the full publication, rather than the press release? https://t.co/MjrA3B3HMY
Oxford vaccine shows good immune response in ages 60s & 70s, w/ hopes it protects age groups @ risk. Findings based on 560 pts: vaccine safe & well tolerated w/ lower reactogenicity in older adults, ie: older age groups could build immunity to the
@Olenkafrenkiel The trial results are here https://t.co/nS1xpXkSg1
RT @LucaFerrettiEvo: @gianlucac1 @ThManfredi I am not involved in any way in the Oxford vaccine, but I feel this campaign is a bit too nega…
@gianlucac1 @ThManfredi I am not involved in any way in the Oxford vaccine, but I feel this campaign is a bit too negative. AFAIK they've been the only ones to: 1) publish on phase 2/3, not just press releases... https://t.co/WaZcF7lmRZ 2) measure effic
@nataliexdean @Dereklowe Interesting points. thanks for sharing. We are nevertheless still missing clinical data from Moderna and Pfizer, while AZN released some in the Lancet paper below. As usual, no final évaluation without final published data. https
@JPThermoz @Drmartyufml @DrGomi elle parle de ces données et il est vrai que je n'ai pas trouve de traces disponible du protocole de PhII/III. A la différence de Pfizer et Moderna, on a des données cliniques a étudier avec AZN, on attend toujours pour les
@2020Smiles @theAliceRoberts @MrGibberish Oxford published their phase 2 results shortly before the phase 3 ‘press release’ https://t.co/0P2KQ0UjTq
RT @ajpollard1: Encouraging results showing the same immune response in our study of ChAdOx1 nCoV-19 in older adults as in younger adults h…
RT @TomChivers: @xtaldave @statsguyuk so, yes, after digging around I find this https://t.co/auNMVv4udG which *appears* (to my inexpert eye…
@ilabassani @Corriere https://t.co/6pJ3NnYWmI Per le sue verifiche sul vaccino.
@dorinileonardo @marco_to66 @FuffaForte Crisanti (ma non solo lui ha criticato il modus operandi di Pfitzer) ha chiesto i dati, che pare in questo caso arriveranno https://t.co/gvXv2XpbCK Cmq, chedere cosa sia cambiato presuppone si parli dello stesso vacc
If you are interested in the study design and the trial of the @AstraZeneca covid-19 vaccine here is the article. #FactsMatter #vaccine https://t.co/o2KlxDX1Pj
Incoerenza totale. Astra ha pubblicato questi dati non completi https://t.co/kvyIhOxuez Ma anche Pfizer li ha pubblicati qui https://t.co/Y7IQwJlIV9 entrambe ci hanno messo meno di 5 anni con le stesse procedure di emergenza. Capite perché è stato perico
RT @Julio19696: @roslemusmartin @JoanmiMmc @Nanisimo @AstraZeneca @UniofOxford Agrego que las vacunas de mRNA necesitan un aparato adiciona…
RT @fedkukso: AZ/Oxford hasta ahora son los únicos que han publicado en una revista científica con revisión de pares (The Lancet) que su va…
@houndcl Have you read this ? https://t.co/0DbKWObSFS
RT @rrjansons: ChadOx1 (Oxfordas vakcīnas kandidāts). Šie pētijumi tik ļoti sirdi sildi šogad. Vēl tikai interesē antivielu titru izmaiņas…
RT @heyafiqasri: @zamirmohyedin source: Gamaleya vaccine: https://t.co/yIbd4LOjqY Oxford/AstraZeneca vaccine: https://t.co/IypBI8Ouv5
@gloquenzi Credo la pubblicazione di questo paper su Lancet (mentre pare che Pfizer e Moderna allo stato si siano limitati a comunicati stampa). Poi non ho nessuna competenza in materia e quindi non so che valore dare a questo studio https://t.co/5wxX8jjd
Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial - The Lancet https://t.co/VGlbSc3rVQ
RT @mark_toshner: For those asking about safety in older populations, hot off press this am from Oxford ChadOx vaccine study- encouraging i…
@halvorz @SkepticalAlpaca @AlexGodofsky no I mean like in the lucre snooker tweet about this https://t.co/JmL4EUlrwB
RT @fedkukso: AZ/Oxford hasta ahora son los únicos que han publicado en una revista científica con revisión de pares (The Lancet) que su va…
RT @fedkukso: AZ/Oxford hasta ahora son los únicos que han publicado en una revista científica con revisión de pares (The Lancet) que su va…
Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial - The Lancet https://t.co/TlqnLIrHXP
Friends, I suggest reading up on the COVID19 vaccines being developed. They will soon be deployed. Read peer-reviewed articles and try to understand. If it's hard, ask friends who are used to reading scientific/medical articles. For now, start with this:
RT @heyafiqasri: @zamirmohyedin source: Gamaleya vaccine: https://t.co/yIbd4LOjqY Oxford/AstraZeneca vaccine: https://t.co/IypBI8Ouv5
@mn_33s Și în articol este link către rezultatele studiului, cu grafice/tabele… Navighează la “Results” de exemplu… e interesant. https://t.co/IuqKZAElCX
@emmakennytv The "Oxford/AstraZeneca" vaccine trial did not include under 18s, but their safety data is in the Lancet paper. https://t.co/YhXFM2fM3F
RT @Gueldor: Artículo sobre la inmunidad de la vacuna de Oxford publicado ayer en The Lancet, por si queréis la información de primera mano…
@MrsAK2017 @allisonpearson @DanielJHannan https://t.co/a5IAygQhiI Table of the study groups is on p126
RT @rrjansons: ChadOx1 (Oxfordas vakcīnas kandidāts). Šie pētijumi tik ļoti sirdi sildi šogad. Vēl tikai interesē antivielu titru izmaiņas…
@adriespo @marcocattaneo @gianlucac1 @ThManfredi Come ha detto qualcuno, a procedure di approvazione eccezionali, trasparenza eccezionale. https://t.co/56aVtRrocZ
so in this piece I say that the low-dose/standard dose regimen was prespecified, but the protocol I linked to seems not to say that. Adam suggests it was a serendipitous finding, which I'm sure is right; I *think* it is prespecified in this protocol here h
@xtaldave @statsguyuk so, yes, after digging around I find this https://t.co/auNMVv4udG which *appears* (to my inexpert eye) to be the thing. N≈12,000, split into "single-dose two-dose" & "two-dose two-dose" groups. It's an appendix to the Lancet paper
Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial https://t.co/XTiIkVMY3t
RT @FarmaMadridAP: (Lancet) Seguridad e inmunogenicidad de la vacuna ChAdOx1n CoV-19 administrada en un régimen de refuerzo primario en adu…
The third is: Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial. https://t.co/k30wCHtVLb
(Lancet) Seguridad e inmunogenicidad de la vacuna ChAdOx1n CoV-19 administrada en un régimen de refuerzo primario en adultos jóvenes y ancianos (COV002): un ensayo simple ciego, aleatorizado, controlado, de fase 2/3 https://t.co/FRaQeNAawg
Questo è quanto pubblicato su #Lancet a proposito del vaccino Oxford/AstraZeneca relativamente alle fasi 1 e 2. Confrontatele pure con i "dati" presenti su "https://t.co/feXt84TjJR". Ah, è in inglese, lingua parlata fluentemente dai bandierini🇮🇪🌟🌟🌟 https:/
RT @JonathanKBall: Just had a quick look at the immunogenicity data, and there are no obvious BIG differences between low and high dose for…
RT @rrjansons: ChadOx1 (Oxfordas vakcīnas kandidāts). Šie pētijumi tik ļoti sirdi sildi šogad. Vēl tikai interesē antivielu titru izmaiņas…
The ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults "appears to be better tolerated in older adults than in younger adults and has similar immunogenicity across all age groups after a boost dose" https://t.co/vgplf1uK
RT @rrjansons: ChadOx1 (Oxfordas vakcīnas kandidāts). Šie pētijumi tik ļoti sirdi sildi šogad. Vēl tikai interesē antivielu titru izmaiņas…
ChadOx1 (Oxfordas vakcīnas kandidāts). Šie pētijumi tik ļoti sirdi sildi šogad. Vēl tikai interesē antivielu titru izmaiņas ilgākā periodā. Atsauce: https://t.co/nT9NtZgFA6 https://t.co/MPXseyVa8C
@CNNSotu @elizcohencnn Here is the actual clinical study on Lancet. Notable that it is the only one published in a major journal whereas Pfizer and Moderna only have press releases. So if there are questions for the Oxford vaccine there should be many mor
RT @heyafiqasri: @zamirmohyedin source: Gamaleya vaccine: https://t.co/yIbd4LOjqY Oxford/AstraZeneca vaccine: https://t.co/IypBI8Ouv5
Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial https://t.co/ikW4oiYdJ6
@zamirmohyedin source: Gamaleya vaccine: https://t.co/yIbd4LOjqY Oxford/AstraZeneca vaccine: https://t.co/IypBI8Ouv5
Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial - The Lancet https://t.co/MUXWQa7xr9
@isajurjo Yo he encontrado este, de la vacuna inglesa. https://t.co/Y5wsV6RjKS
@PABLITOQO @askomartin La evidencia pana. https://t.co/U5293v1Pat
A single-blind, randomized control, phase 2/3 trial in the UK reported a chimpanzee adenovirus-vectored vaccine, ChAdOx1 nCoV-19, could induce antibody responses against the SARS-CoV-2 spike protein and maintain the response for 28 days. https://t.co/SHkfJ
RT @mukeshkapila: The #Oxford #COVID19 vaccine group are to be commended for publishing their results in peer-reviewed medical journals an…
Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial. https://t.co/YNT1I2Ey9P
@Marco__P_Shite Trial conducted may to aug, results published 18/11/20. #science takes time to PROVE things work. https://t.co/9ew1C7VSk9 Manufacturing scale up will take more time to achieve a stable product for distribution, and establish a shelf life.
RT @drphilhammond: Well done the Oxford/AstraZeneca team for releasing their vaccine results through a peer reviewed journal, rather than a…
Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial - The Lancet https://t.co/3F7voYXtDP
RT @fedkukso: AZ/Oxford hasta ahora son los únicos que han publicado en una revista científica con revisión de pares (The Lancet) que su va…
RT @fedkukso: AZ/Oxford hasta ahora son los únicos que han publicado en una revista científica con revisión de pares (The Lancet) que su va…
RT @fedkukso: AZ/Oxford hasta ahora son los únicos que han publicado en una revista científica con revisión de pares (The Lancet) que su va…
AZ/Oxford hasta ahora son los únicos que han publicado en una revista científica con revisión de pares (The Lancet) que su vacuna candidata produce un respuesta inmune en adultos mayores. Paper: https://t.co/uWwWCimOKq
RT @MaxCRoser: New results from the Oxford vaccine trial just got published in The Lancet. It studied whether the immune response provoked…
Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002) @TheLancet #COVID19 https://t.co/gUjVUlFlMq
@MyrneStol @martijnkatan @jsm2334 Figure 5 and 6 of their publication in the lancet. Figure 6 shows the correlation of pre-boost nAb titers against chadox vs post boost nAb against spike and elispot response. Not straight forward to interpret but I don’t c
RT @PabloFuente: #COVID19 Los datos, que se conocieron en parte el mes pasado, y que ahora son ahora publicados en su totalidad en The Lanc…
Oxford–AstraZenecaのワクチンの中間解析はプレスリリースと同時に論文もパブリッシュになってるね。 https://t.co/5oWUZAF93R
RT @PabloFuente: #COVID19 Los datos, que se conocieron en parte el mes pasado, y que ahora son ahora publicados en su totalidad en The Lanc…
RT @ajpollard1: Encouraging results showing the same immune response in our study of ChAdOx1 nCoV-19 in older adults as in younger adults h…
🔴Publication dans The Lancet du résultat intermédiaire de tolérance et d'efficacité du vaccin d'AstraZeneca. L'étude montre une réponse immunitaire égale sur tous les groupes d'âge, y compris >70 ans, et suggère un vaccin sans danger et bien toléré. 1/2
RT @r_challis: Phase 2 data published in the lancet today. Really proud of all the team @southamptonCRF @UHSFT where we worked so hard to h…
@LandolfThore @Karl_Lauterbach Hier ist die Originalpublikation: https://t.co/SvTHpPK7Yl
#Vaccitech Safety and immunogenicity of #ChAdOx1 nCoV-19 vaccine vaccine against #SARSCoV2 administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial Published: November 18, 2020 https://
RT @mukeshkapila: The #Oxford #COVID19 vaccine group are to be commended for publishing their results in peer-reviewed medical journals an…
@tigerjamjar
Una preguntina @sanidadgob Si los ancianos son los pacientes de mas riesgo y en los ensayos sobre vacunas estan infrarrepresentados en número y caracteristicas. Por qué motivo van a ser los primeros en vacunarse ? 🤔 https://t.co/3oHLAEtx9R
@D9Herbs That was short hand for indicating what the 90% efficacy results translate to. Vaccine effectiveness is measured on a population level (9 in 10), not individual (ie not 90% effective in each person) Detailed here: https://t.co/l3kGoxUQ58 Full pape
Deus nos proteja
RT @DrMattMcCarthy: AstraZeneca is seen as the favorite for low/middle income countries. I see another opportunity. They've published data…
Vaccin covid!
Safety of the COVID vaccine https://t.co/T4i3vbdzHz
Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial https://t.co/VTPFupQyBP
ChAdOx1•S is Chimpanzee proteins 🤮🤮🤮🤮 #fuckavaccine #itrustmyimmunesystem https://t.co/QNHV8isJXR https://t.co/ncnxwE9HdV
Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial. https://t.co/cuyvuBDkVx
RT @macesari: "...Early phase studies in older adults require healthy volunteers to be enrolled for safety assessments [...]. Therefore, we…
@roslemusmartin @JoanmiMmc @Nanisimo @AstraZeneca @UniofOxford Agrego que las vacunas de mRNA necesitan un aparato adicional de electroporacion para introducir el mensajero en la celula. Ademas de este se necesita capacitacion. Creo que informacion de Azt
@Medium Of 300 clinical trial participants ONE was black. I agree with William. We need diversity in testing and disaggregated data. https://t.co/Yf7vr2mKQU
(figure 5 from https://t.co/dpbBj99jJA) if the theory is that immunity to the vector is blunting the response, why wouldn't that already be visible here?
@stgoldst @notdred @angie_rasmussen In the earlier data, there was perhaps a difference in antibody titers between low-dose and high-dose groups. The low-dose group looks like it had close to double the antibody titer at 28 days in the 18-55 cohort here (
RT @DrMattMcCarthy: AstraZeneca is seen as the favorite for low/middle income countries. I see another opportunity. They've published data…
@ninabecks1 Peccato che i dati siano già pubblici. Così, aprendo la prima pagina di Lancet, ad esempio: https://t.co/eJuXzA3S1d
@mrcllznn @luciodigaetano Ma anche no. I dati sono già pubblici. Così tanto per aprire la prima pagina di Lancet: https://t.co/eJuXzA3S1d